Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race [Seeking Alpha]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Seeking Alpha
cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived ß-cell therapy, CNTY-813. IPSC's Allo-Evasion platform uniquely targets T-cell, NK-cell, and humoral immunity, potentially offering superior long-term engraftment and immune escape versus competitors like SANA, VRTX, and CRSP. With cash runway to Q1 2029 and a recent $135M PIPE from major biotech funds, IPSC is well-capitalized to advance its T1DM program toward IND submission in 2026 and initial clinical data in 2027. Key risks include preclinical status, intense competition, manufacturing scale-up, and long-term durability/safety concerns, but the large T1DM market and comprehensive immune evasion approach offer substantial upside if successful. wildpixel/iStock via Getty Images Thesis overview Century Therapeutics ( IPSC ) is developing induced pluripotent stem cell (iPSC)-derived therapies for the treatment of type I diabetes mellitus (T1DM), autoimmune diseases and oncology indications. Their i
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IPSC&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics (NASDAQ:IPSC) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IPSC&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics (NASDAQ:IPSC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
IPSC
Earnings
- 11/13/25 - Miss
IPSC
Sec Filings
- 2/5/26 - Form 4
- 2/5/26 - Form S-3
- 2/4/26 - Form 4
- IPSC's page on the SEC website